文献速递癫痫脑血管病

未治疗脑海绵状血管畸形的癫痫发作与癫痫:前瞻性人群队列研究

Seizures and Epilepsy in Patients With Untreated Cerebral Cavernous Malformations: A Prospective, Population-Based Cohort Study.
PubMed 文献 · Neurology · 2025-11-13

该研究基于苏格兰人群队列,纳入1999-2010年新诊断的300例脑海绵状血管畸形(CCM)患者,在未干预情况下中位随访15年。结果显示首次癫痫发作风险低(10年6%),但首次非诱因发作后10年复发风险达80%,抗癫痫药物可降低复发风险;多数CCM相关癫痫患者10年内可达2年或5年无发作。

要点

  • CCM患者首次癫痫发作风险低,10年累计仅6%。
  • 首次非诱因发作后10年复发风险高达80%,应诊断CCM相关癫痫。
  • 抗癫痫药物可显著降低首次发作后的复发风险(aHR 0.36)。

核心结论

  • CCM患者首次癫痫发作风险低,但首次非诱因发作后复发风险高,支持诊断为CCM相关癫痫。
  • 多数CCM相关癫痫患者10年内可实现2年及5年无发作。

研究设计与样本

  • 基于苏格兰人群的前瞻性队列研究,纳入1999-2003年或2006-2010年新诊断的300例CCM患者,中位年龄44岁,53%女性。
  • 从初始表现开始前瞻性随访,期间未对CCM进行干预,中位随访15年。

主要发现

  • 98例(33%)在任一表现后出现癫痫发作,与年龄(每增加10岁aHR 0.82,95%CI 0.71-0.95,p=0.008)及初始表现为癫痫发作(aHR 12.94,95%CI 7.11-23.52,p<0.001)相关。
  • 189例初始无癫痫发作的患者中,10年内首次癫痫发作风险为6%(95%CI 2%-9%)。
  • 64例首次非诱因发作患者10年内复发风险为80%(95%CI 70%-91%),首次发作后使用抗癫痫药物者复发风险更低(aHR 0.36,95%CI 0.19-0.70,p=0.003)。
  • 110例CCM相关癫痫患者中,10年内82%(95%CI 74%-91%)达2年无发作,62%(95%CI 51%-72%)达5年无发作,多数为抗癫痫药物单药治疗(分别为44/75 [59%]和40/60 [67%])。

临床怎么用

  • 对CCM患者首次非诱因癫痫发作后应诊断CCM相关癫痫,并考虑启动抗癫痫药物治疗以降低复发风险。
  • 应告知CCM相关癫痫患者长期预后较好,多数可达长期无发作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Treatment decisions for patients with epileptic seizures due to cerebral cavernous malformations (CCMs) are challenging because of a paucity of studies. We aimed to assess the rates and risk factors of CCM-related seizures during long-term follow-up without CCM intervention. METHODS: This population-based study included people aged 16 years or older in Scotland who were newly diagnosed with CCM during 1999-2003 or 2006-2010, using brain MRI or pathology. From the initial presentation that led to CCM diagnosis, during prospective follow-up without CCM intervention, we analyzed the rates and risk factors for epileptic seizure(s) after any presentation, a first-ever epileptic seizure, seizure recurrence after a first unprovoked epileptic seizure, and 2-year/5-year seizure freedom among patients with CCM-related epilepsy (CRE). RESULTS: We included 300 patients with CCM (median age 44 years, interquartile range [IQR] 32-57, 159 [53%] female). During a median follow-up of 15 years (IQR 8-20), 98 (33%) patients experienced epileptic seizure(s) after any presentation, which was associated with age (adjusted hazard ratio [aHR] 0.82, 95% CI 0.71-0.95, per 10-year increment, p = 0.008) and initial presentation with epileptic seizure(s) (aHR 12.94, 95% CI 7.11-23.52, p < 0.001). Of 189 patients who had never experienced epileptic seizures at initial presentation, 6% (95% CI 2%-9%) experienced a first-ever epileptic seizure within 10 years. For 64 patients with a first unprovoked epileptic seizure at initial presentation or during follow-up, the risk of seizure recurrence within 10 years was 80% (95% CI 70%-91%), which was lower with antiseizure medicine(s) therapy after the first seizure (aHR 0.36, 95% CI 0.19-0.70, p = 0.003). Among 110 patients who had CRE at initial presentation or developed CRE during follow-up, 82% (95% CI 74%-91%) became 2-year seizure-free and 62% (95% CI 51%-72%) 5-year seizure-free at 10 years, mostly while on antiseizure medicine monotherapy (44/75 [59%] and 40/60 [67%], respectively). DISCUSSION: The risk of a first-ever epileptic seizure from CCM is low. Four of 5 patients who experience a first unprovoked epileptic seizure develop a recurrent seizure within 10 years, justifying diagnosis of CRE after a first unprovoked epileptic seizure due to CCM. Most of the patients with CRE achieve 2-year/5-year seizure freedom within 10 years. These long-term findings can inform patients and guide clinical practice.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sandmann ACA, Vandertop WP, White PM, et al. Seizures and Epilepsy in Patients With Untreated Cerebral Cavernous Malformations: A Prospective, Population-Based Cohort Study. Neurology. 2025. PMID: 41232061. doi:10.1212/WNL.0000000000214387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。